IL154279A0 - Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation - Google Patents

Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Info

Publication number
IL154279A0
IL154279A0 IL15427901A IL15427901A IL154279A0 IL 154279 A0 IL154279 A0 IL 154279A0 IL 15427901 A IL15427901 A IL 15427901A IL 15427901 A IL15427901 A IL 15427901A IL 154279 A0 IL154279 A0 IL 154279A0
Authority
IL
Israel
Prior art keywords
prophylaxis
medicament
manufacture
treatment
receptor antagonists
Prior art date
Application number
IL15427901A
Other languages
English (en)
Original Assignee
Glaxosmithkline Lab Sas
Glaxo Group Ltd
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Glaxosmithkline Lab Sas, Glaxo Group Ltd, Smithkline Beecham Corp filed Critical Glaxosmithkline Lab Sas
Publication of IL154279A0 publication Critical patent/IL154279A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15427901A 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation IL154279A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Publications (1)

Publication Number Publication Date
IL154279A0 true IL154279A0 (en) 2003-09-17

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15427901A IL154279A0 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Country Status (16)

Country Link
US (3) US20050032866A1 (enExample)
EP (1) EP1311295A2 (enExample)
JP (2) JP2004505930A (enExample)
KR (1) KR20030027010A (enExample)
CN (1) CN100413539C (enExample)
AU (1) AU781276B2 (enExample)
BR (1) BR0113073A (enExample)
CA (1) CA2418904A1 (enExample)
CZ (1) CZ2003366A3 (enExample)
HU (1) HUP0303075A3 (enExample)
IL (1) IL154279A0 (enExample)
MX (1) MXPA03001210A (enExample)
NO (1) NO20030588L (enExample)
NZ (1) NZ524108A (enExample)
PL (1) PL365048A1 (enExample)
WO (1) WO2002011766A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007857A (es) * 2002-02-14 2004-10-15 Glaxo Group Ltd Composicion farmaceutica que comprende n-((1-butil -4-piperidinil) metil)-3, 4-dihidro-2h -(1, 3)oxazino (3, 2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco.
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
EP3176164B1 (en) 2014-07-30 2019-08-21 Aetas Pharma Co. Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
CA2118812C (en) * 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
DE69325167T2 (de) * 1992-03-12 2000-01-20 Smithkline Beecham P.L.C., Brentford Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
MX9301837A (es) * 1992-03-31 1994-02-28 Glaxo Group Ltd Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende.
SK116394A3 (en) * 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
ATE171446T1 (de) * 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
ES2151743T3 (es) * 1996-08-16 2001-01-01 Smithkline Beecham Plc Procedimiento para la preparacion de n-((1-n-butil-4-piperidinil)metil)-3,4-dihidro-2h-(1,3)-oxazino(3,2-a)indol-10-carboxamida y las sales y productos intermedios en el procedimiento.
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Also Published As

Publication number Publication date
CN100413539C (zh) 2008-08-27
BR0113073A (pt) 2004-06-22
HUP0303075A3 (en) 2007-03-28
JP2004505930A (ja) 2004-02-26
EP1311295A2 (en) 2003-05-21
MXPA03001210A (es) 2004-08-12
PL365048A1 (en) 2004-12-27
US20050032866A1 (en) 2005-02-10
WO2002011766A2 (en) 2002-02-14
WO2002011766A3 (en) 2002-08-01
NO20030588D0 (no) 2003-02-06
NO20030588L (no) 2003-04-03
US20070015769A1 (en) 2007-01-18
CZ2003366A3 (en) 2004-04-14
US20080125422A1 (en) 2008-05-29
CN1468112A (zh) 2004-01-14
AU781276B2 (en) 2005-05-12
AU7652901A (en) 2002-02-18
HUP0303075A2 (hu) 2003-12-29
NZ524108A (en) 2004-11-26
CA2418904A1 (en) 2002-02-14
KR20030027010A (ko) 2003-04-03
JP2007145869A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
IL183853A0 (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias
IL196301A0 (en) Medicament for the treatment of hapatitis c
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AU4323301A (en) Surgical monitor
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
IL154802A0 (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
IL154279A0 (en) Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
SI1408964T1 (sl) Uporaba 2- 5-(4-fluorofenil)-3-piridilmetil-aminometil -kromana in njegovih fizioloĺ ko sprejemljivih soli
ZA200301031B (en) Use of 5HT4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation.
HK1057326A (en) Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
HUP0202339A3 (en) Use of cortisol antagonists in the treatment of heat failure
MXPA02012942A (es) Compuestos nuevos de bispidina y su uso en el tratamiento de arritmias cardiacas.
EP1579867A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF ISCHEMIC HEART FAILURE
IL146752A0 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
IL146754A0 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
AU782863C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU782870C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
IL146753A0 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
IL146751A0 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL158809A0 (en) The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
IL164388A (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias